Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer

Gynecologic and Obstetric Investigation

Volumn 75, Issue 4, 2013, Pages 263-267

  No, Jae Hong ^a   Moon, Jeong Min ^b   Kim, Kidong ^a   Kim, Yong Beom ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

Author keywords

Biomarker; Ovarian cancer; Prognosis; Serum; Soluble CD163

Indexed keywords

CD163 ANTIGEN; ANTINEOPLASTIC METAL COMPLEX;

ADULT; ARTICLE; ASCITES FLUID CYTOLOGY; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE GENITAL TRACT CYTOLOGY; LEUKOCYTE COUNT; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; RISK FACTORS; SOLUBILITY;

EID: 84878849051     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000349892     Document Type: Article

References (25)

1. Holschneider CH, Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Baird L, Terskikh A: The tumor microenvironment. Adv Exp Med Biol 2010; 671: 67-73.
4. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al: A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007; 178: 8183-8194.
5. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 2005; 14: 425- 431.
6. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000; 7: 263- 269.
7. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A: Tumor-associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000; 17: 445-451.
8. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009; 59: 300-305.
9. Moestrup SK, Moller HJ: CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36: 347-354.
10. Van Gorp H, Delputte PL, Nauwynck HJ: Scavenger receptor CD163, a Jack-of-alltrades and potential target for cell-directed therapy. Mol Immunol 2010; 47: 1650-1660.
11. Droste A, Sorg C, Hogger P: Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteinerich family. Biochem Biophys Res Commun 1999; 256: 110-113.
12. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK: Plasma level of the macrophage- derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004; 72: 135- 139.
13. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, et al: Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 2006; 34: 2561-2566.
14. Moller HJ, Gronbaek H, Schiodt FV, Holland- Fischer P, Schilsky M, Munoz S, et al: Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007; 47: 671-676.
15. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, et al: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27: 3330-3337.
16. Jee BC, Suh CS, Kim SH, Moon SY: Serum soluble CD163 and interleukin-6 levels in women with ovarian endometriomas. Gynecol Obstet Invest 2008; 66: 47-52.
17. Pang B, Zhou X, Yu H, Dong M, Taghizadeh K, Wishnok JS, et al: Lipid peroxidation dominates the chemistry of DNA adduct formation in a mouse model of inflammation. Carcinogenesis 2007; 28: 1807-1813.
18. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
19. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al: Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor-κB. Proc Natl Acad Sci USA 2009; 106: 14978-14983.
20. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
21. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
22. Bingle L, Brown NJ, Lewis CE: The role of tumour- associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
23. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al: A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009; 4:e6562.
24. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK: Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia 2009; 11: 136-144.
25. Wang X, Deavers M, Patenia R, Bassett RL Jr, Mueller P, Ma Q, et al: Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Transl Med 2006; 4: 30.